P1618: Real-World Data on Emicizumab: Correlation Between Drug Plasma Levels, Global Procoagulant Status and Spontaneous Joint Annualized Bleeding Rate

Abstract

Emicizumab has improved the management of patients with hemophilia A with or without inhibitors. However, real-world data on drug plasma levels and their correlation with thrombin generation, viscoelastic clotting capacity and spontaneous joint annualized bleeding rate (SJABR) are scarce.